These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 16369246)

  • 1. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
    Mouridsen HT; Robert NJ
    MedGenMed; 2005 Aug; 7(3):20. PubMed ID: 16369246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98.
    Koeberle D; Thuerlimann B
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):55-66. PubMed ID: 17912636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of aromatase inhibitors in the adjuvant setting.
    Perez EA
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):75-89. PubMed ID: 17912638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
    Goss PE; Ingle JN; Pritchard KI; Robert NJ; Muss H; Gralow J; Gelmon K; Whelan T; Strasser-Weippl K; Rubin S; Sturtz K; Wolff AC; Winer E; Hudis C; Stopeck A; Beck JT; Kaur JS; Whelan K; Tu D; Parulekar WR
    N Engl J Med; 2016 Jul; 375(3):209-19. PubMed ID: 27264120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial.
    Mansel R; Locker G; Fallowfield L; Benedict A; Jones D
    Br J Cancer; 2007 Jul; 97(2):152-61. PubMed ID: 17622238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane.
    Bertelsen BE; Almås B; Fjermeros K; Viste K; Geisler SB; Sauer T; Selsås K; Geisler J
    Breast Cancer Res Treat; 2024 Jul; 206(2):347-358. PubMed ID: 38649619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer.
    Cuzick J
    Expert Rev Anticancer Ther; 2007 Aug; 7(8):1089-94. PubMed ID: 18028017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Livingston RB; Davidson NE; Perez EA; Chavarri-Guerra Y; Cameron DA; Pritchard KI; Whelan T; Shepherd LE; Tu D
    Ann Oncol; 2013 Feb; 24(2):355-361. PubMed ID: 23028039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy.
    Markopoulos C; Dafni U; Misitzis J; Zobolas V; Tzoracoleftherakis E; Koukouras D; Xepapadakis G; Papadiamantis J; Venizelos B; Antonopoulou Z; Gogas H
    Breast Cancer Res; 2009; 11(3):R35. PubMed ID: 19531217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis.
    Yu Z; Guo X; Jiang Y; Teng L; Luo J; Wang P; Liang Y; Zhang H
    Breast Cancer; 2018 Jan; 25(1):8-16. PubMed ID: 28755088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.
    Sgroi DC; Carney E; Zarrella E; Steffel L; Binns SN; Finkelstein DM; Szymonifka J; Bhan AK; Shepherd LE; Zhang Y; Schnabel CA; Erlander MG; Ingle JN; Porter P; Muss HB; Pritchard KI; Tu D; Rimm DL; Goss PE
    J Natl Cancer Inst; 2013 Jul; 105(14):1036-42. PubMed ID: 23812955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
    Mamounas EP; Bandos H; Rastogi P; Lembersky BC; Jeong JH; Geyer CE; Fehrenbacher L; Chia SK; Brufsky AM; Walshe JM; Soori GS; Dakhil SR; Wade JL; McCarron EC; Swain SM; Wolmark N
    J Natl Cancer Inst; 2023 Nov; 115(11):1302-1309. PubMed ID: 37184928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials.
    Markopoulos CJ
    Cancer Metastasis Rev; 2010 Dec; 29(4):581-94. PubMed ID: 20830503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysis.
    Petrelli F; Cavallone M; Dottorini L
    Eur J Cancer; 2023 Nov; 193():113322. PubMed ID: 37769477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review.
    Monnier A
    Ther Clin Risk Manag; 2009 Oct; 5(5):725-38. PubMed ID: 19774214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer.
    Aydiner A; Tas F
    Trials; 2008 Jul; 9():47. PubMed ID: 18664277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.
    Speirs V; Viale G; Mousa K; Palmieri C; Reed SN; Nicholas H; Cheang M; Jassem J; Lønning PE; Kalaitzaki E; van de Velde CJH; Rasmussen BB; Verhoeven DM; Shaaban AM; Bartlett JMS; Bliss JM; Coombes RC;
    Ann Oncol; 2015 Sep; 26(9):1890-1897. PubMed ID: 26002610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer.
    Nabholtz JM; Mouret-Reynier MA; Durando X; Van Praag I; Nayl B; Ferriere JP; Chollet P
    Indian J Surg Oncol; 2010 Jan; 1(1):19-26. PubMed ID: 22930614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).
    Wagner LI; Zhao F; Goss PE; Chapman JW; Shepherd LE; Whelan TJ; Mattar BI; Bufill JA; Schultz WC; LaFrancis IE; Nagargoje GG; Vemuri R; Nikcevich DA; Sledge GW; Cella D
    Breast Cancer Res Treat; 2018 Jun; 169(3):537-548. PubMed ID: 29455298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequencing of aromatase inhibitors.
    Bertelli G
    Br J Cancer; 2005 Aug; 93 Suppl 1(Suppl 1):S6-9. PubMed ID: 16100523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.